Monoclonal antibodies for COVID-19 begin neutralizing the virus almost immediately after infusion, with most patients noticing symptom improvement within one to three days. In clinical studies, 70% of patients reported better symptoms within three days of treatment, and many improved within 48 hours.
What Happens in the First 24 Hours
The speed of monoclonal antibodies is striking at the cellular level. Within a day of treatment, researchers found that zero out of 28 treated patients still had live, culturable virus in their nasal passages, compared to 41% of placebo patients who were still shedding infectious virus. That difference was statistically dramatic. By day two, all treated patients remained culture-negative, while 18% of untreated patients were still producing live virus.
This means the antibodies start disabling the virus almost right away, even though your nose may still test positive on a swab for a few more days. That’s because nasal viral loads (the raw amount of viral genetic material detected) drop more gradually, taking roughly two to three days to show a measurable decline. The key distinction is that the virus you’re shedding becomes non-infectious well before it fully clears from your system.
When You’ll Actually Feel Better
Most people notice a real change in how they feel within one to three days. In a study tracking patients during the Delta and Omicron waves, 75% of one group and 100% of another reported symptom improvement within 48 hours of their infusion. Across the broader study population, 70% improved within three days.
That said, “improvement” doesn’t mean full recovery overnight. Fatigue and mild respiratory symptoms can linger beyond that initial window. The treatment is designed to prevent the disease from getting worse, not to make you feel 100% the next morning. For high-risk patients, the real benefit is avoiding the steep decline that can lead to hospitalization.
How They Prevent Severe Illness
The strongest evidence for monoclonal antibodies has always been their ability to keep high-risk patients out of the hospital. Real-world data showed that single-antibody treatments reduced hospitalization by 40% to 60%. Combination antibody therapies performed even better: one analysis found a 70% reduction in hospitalization among high-risk patients compared to matched controls who received no treatment. These treatments also significantly reduced ICU admissions and deaths.
Timing matters enormously for these outcomes. Monoclonal antibodies work best when given early in the course of illness, ideally within the first several days of symptom onset. The earlier the antibodies arrive, the less virus there is to fight, and the less damage has been done to your lungs and other organs. Once a patient is already severely ill and hospitalized, the window for this type of treatment has largely closed.
How the Antibodies Stop the Virus
The SARS-CoV-2 virus uses a protein on its surface, the spike protein, to latch onto a receptor on your cells called ACE2. Once the spike protein locks in, the virus fuses with the cell membrane and slips inside to start replicating. Monoclonal antibodies work by physically blocking this connection. They bind to the spike protein’s attachment point so tightly that the virus can no longer grab onto your cells.
Some antibodies target additional steps in the infection process, disrupting the virus even after it has made initial contact with a cell. Because these are lab-engineered antibodies delivered in large concentrations through an IV, they flood the bloodstream much faster than your immune system could produce its own. That’s why the effect is so rapid compared to waiting for your body to mount a natural defense.
What the Infusion Experience Looks Like
The infusion itself is a relatively short outpatient procedure. You receive the antibodies through an IV line, and afterward, you’re monitored for about one to two hours. This observation period exists because infusion-related reactions, while uncommon, can occur during or up to 24 hours after treatment.
The most common side effects are mild: rash (affecting roughly 1% of patients), diarrhea (about 2%), and itching (under 1%). More serious reactions like difficulty breathing, significant drops in blood pressure, or throat swelling are possible but rare. Symptoms to watch for in the hours after your infusion include fever, chills, nausea, headache, dizziness, and hives.
Current Availability and Variant Challenges
One of the biggest complications with monoclonal antibody treatment for COVID has been the virus’s ability to mutate. Several antibody therapies that worked well against earlier variants lost effectiveness as new strains emerged, leading to their authorizations being pulled. As of recent FDA authorizations, the monoclonal antibody landscape for COVID treatment has narrowed significantly.
Pemivibart is currently authorized as a preventive option for people aged 12 and older who are moderately or severely immunocompromised and unlikely to respond adequately to vaccination. It’s given as an IV infusion for pre-exposure protection rather than treatment of active infection. The CDC actively monitors circulating variants to assess whether they might reduce pemivibart’s effectiveness. For treating active COVID infections, antiviral medications have largely taken over the role that monoclonal antibodies filled earlier in the pandemic.